Dynamic Contrast-Enhanced Magnetic Resonance Imaging Rapidly Indicates Vessel Regression in Human Squamous Cell Carcinomas Grown in Nude Mice Caused by VEGF Receptor 2 Blockade with DC101  by Kiessling, Fabian et al.
Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Rapidly Indicates Vessel Regression in Human Squamous
Cell Carcinomas Grown in Nude Mice Caused by
VEGF Receptor 2 Blockade with DC1011
Fabian Kiessling*, Nabeel Farhan*, Matthias P. Lichy y, Silvia Vosseler z, Melanie Heilmann*, Martin Krix y,
Peter Bohlen§, Dan W. Miller b, Margareta M. Mueller z, Wolfhard Semmler*, Norbert E. Fusenig z
and Stefan Delorme y
Divisions of *Medical Physics in Radiology, yRadiology and zCarcinogenesis and Differentiation, German Cancer
Research Center, INF 280, Heidelberg 96121, Germany; § ImClone Systems, Incorporated, 180 Varick Street, New
York, NY 10014, USA; bDepartment of Ophthalmology, University Heidelberg, INF 400, Heidelberg 69120, Germany
Abstract
The purpose of our study was the investigation of early
changes in tumor vascularization during antiangiogen-
ic therapy with the vascular endothelial growth factor
(VEGF) receptor 2 antibody (DC101) using dynamic
contrast-enhanced magnetic resonance imaging (DCE
MRI). Subcutaneous heterotransplants of human skin
squamous cell carcinomas in nude mice were treated
with DC101. Animals were examined before and repeat-
edly during 2 weeks of antiangiogenic treatment using
Gd-DTPA–enhanced dynamic T1-weighted MRI. With a
two-compartment model, dynamic data were parame-
terized in ‘‘amplitude’’ (increase of signal intensity
relative to precontrast value) and kep (exchange rate
constant). Data obtained by MRI were validated by
parallel examinations of histological sections immu-
nostained for blood vessels (CD31). Already 2days after
the first DC101 application, a decrease of tumor
vascularization was observed, which preceded a re-
duction of tumor volume. The difference between
treated tumors and controls became prominent after 4
days, when amplitudes of treated tumors were de-
creased by 61% (P = .02). In line with change of
microvessel density, the decrease in amplitudes was
most pronounced in tumor centers. On day 7, the mean
tumor volumes of treated (153 ± 843 mm3) and control
animals (596 ± 384 mm3) were significantly different
(P = .03). After 14 days, treated tumors showed further
growth reduction (83 ± 93 mm3), whereas untreated
tumors (1208 ± 822mm3) continued to increase (P = .02).
Our data underline the efficacy of DC101 as anti-
angiogenic treatment in human squamous cell carci-
noma xenografts in nudemice and indicate DCEMRI as
a valuable tool for early detection of treatment effects
before changes in tumor volume become apparent.
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Introduction
Angiogenesis is an essential step for the growth and spread of
malignant tumors [1–3]. As a consequence, heightened inter-
est has been placed on the mechanisms controlling this pro-
cess and the identification of antiangiogenic targets [4,5].
Angiogenic inhibitors have been developed and successfully
applied in syngenic and heterotransplant tumor models [6–8]
and some of these drugs already entered phase I clinical trials
[4,9–11]. Many of these inhibitors are directed against the
vascular endothelial growth factor (VEGF) or its receptors,
which are considered to play a key role in angiogenesis
[6,12]. VEGF is both proangiogenic and antiapoptotic for
endothelial cells, induces the development of immature blood
vessels [13], and increases vessel permeability [14,15]. Inhibi-
tion of VEGF and its receptors stops the formation of new
vessels in tumors, induces the regression of existing tumor
vessels, and as a consequence leads to the collapse and
necrotic degeneration of tumors [6,12].
Important for clinical application in antiangiogenic therapy is
the early assessment of therapeutic effects for the prediction of
therapy response and the individualization of treatment to
impart confidence in drug development and dose finding
[16,17]. Thus, functional monitoring of the effects of angiogenic
inhibitors on tumor vasculature has become the focus of both
basic and clinical research. Magnetic resonance imaging (MRI)
provides several techniques for examining tissue vasculariza-
tion and perfusion [18–22] that have already been successfully
applied in patients for the characterization of tumors and
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monitoring of therapy response. In this regard, dynamic
contrast-enhanced T1-weighted MRI, in combination with
postprocessing of data using an open pharmacokinetic
two-compartment model, has shown potential in clinical
studies of the breast [23,24], cervix [25,26], and bone
marrow [27].
However, the assessment of tissue perfusion in cancer
still needs optimization. Dynamic parameters need to be
validated in different tumor types with variable vascular
architecture and reliable parameters for treatment monitor-
ing have to be established. Furthermore, the ideal time point
to start treatment monitoring using dynamic MR techniques
has to be elucidated. For this purpose, in particular for
monitoring during therapeutic intervention with antiangio-
genic drugs, the use of small animals is required. Noninva-
sive dynamic MR studies of tumor angiogenesis in animals
such as the mouse, however, are more difficult due to small
animal and tumor volumes, and therefore usually need to be
performed in dedicated animal MR scanners [20,28,29].
Although such studies give valuable information about tumor
biology and also offer the opportunity to evaluate and im-
prove new MR techniques or new contrast agents [30,31],
their applicability is restricted due to the limited number of
animal scanners available. We decided to perform our
experiments on a clinical 1.5-T whole-body MR scanner
using a self-developed small animal transmit-and-receive
volume resonator, and were previously able to show that
examination of mice can be done successfully and reliably
with this setup [32]. Doing so, we expected that this setting
would better match with clinical MR studies.
It was previously shown by histological analysis that the
therapeutic VEGF receptor 2 antibody DC101 effectively
inhibits tumor vascularization manifested in a marked de-
crease of tumor vessel density [33]. Concomitantly with this
inhibition of angiogenesis, the antibody treatment also
inhibited tumor invasion [33]. Although previous studies
examined late effects of VEGF receptor 2 inhibition by
histological methods (i.e., ex vivo), the purpose of our study
was to monitor in vivo the early effects (3 hours–2 weeks) of
this antibody treatment by dynamic T1-weighted contrast-
enhanced MRI. For comparative validation of the MR results,
histological specimens were obtained at the same time
intervals as the MR measurements, from a second set of
identically treated tumor-bearing animals.
Materials and Methods
Tumor Implantation and VEGFReceptor Antibody Treatment
All experiments were approved by the governmental
review committee on animal care. Immortal human skin
keratinocytes (HaCaT) tumorigenically transformed by Ha-
ras transfection were selected for tumor progression by
repeated in vivo passaging as nude mouse heterotrans-
plants (HaCaT-ras-A-5RT3) [34,35]. Tumors were induced
by subcutaneous injection of 2  105 cells, 0.5 to 1.0 cm
behind the neck of nude mice. Starting at day 15 after tumor
induction (mean tumor volume: 92 mm3), mice were treated
with a solution of 800 mg of VEGF receptor antibody (DC101;
ImClone Systems, Incorporated, New York, NY) in 60 ml of
NaCl, injected subcutaneously every other day [33]. In
control animals, 60 ml of NaCl solution without DC101 was
injected subcutaneously at identical time points. The effect of
an irrelevant antibody control versus DC101 was examined
previously [33] and found to have no effect. Intraperitoneal
injection of antibody was evaluated as a second route of
administration, and was found to yield the same results
during the observation period (data not shown). The subcu-
taneous injection was given at a distance more than 1.5 cm
from the tumor borders.
Examination Protocol
A total of 12 nude mice with subcutaneous squamous cell
carcinomas (SCCs) was examined by MRI starting on day 15
after subcutaneous injection of tumor cells. Six were treated
with the VEGF receptor antibody and six were kept as control
animals. Six additional mice (control/therapy: n = 3/3) were
carried as potential replacements (Table 1).
Six animals of the control and treatment groups were
examined at each time point using MRI, with the exception of
1- and 3-hour time points (Table 1). At 1 and 3 hours, only
three mice each of the therapy group were investigated
because the contrast agent would not have been excreted
by the organism within 3 hours.
The baseline MR examination was performed 1 day
before starting treatment with the VEGF receptor antibody.
Table 1. Examination Protocol of the Study.
Mouse Hours, days
0
hour
1
hour
3
hours
1
day
2
days
4
days
7
days
14
days
Follow-up group
Treated 1 e e e e e e, r
2 e e e e e e f, r
3 e e e e e e e, r
4 e e e e e e e, r
5 e e e e e e e, r
6 e e e e e e e, r
R1-3 r
Untreated 7 e e e f e e e, r
8 e e e e e e e, r
9 e e e e e e e, r
10 e e e e e e e, r
11 e e e e e e e, r
12 e e e e e e e, r
R4-6 r
Correlation group
Treated 1 e, r
2 e, r
3 e, r
4 e, r
5 e, r
Untreated 6 e, r
7 e, r
8 e, r
9 e, r
10 e, r
A group of 12 animals (six treated) was examined repeatedly using MRI. The
correlation group was examined once by MRI and tumors were removed for
histological evaluation after examination.
R, reserve group to replace dropouts; e, successful examination;
f, examination failed; r, tumor removed for histology.
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Follow-up examinations took place 1 hour (treated mice:
n = 3), 3 hours (treated mice: n = 3), and 1, 2, 4, 7, and 14
days following the first anti–VEGF receptor antibody appli-
cation. One treated and one control animal were sacrificed
7 days after the start of treatment for histological assess-
ment. All other tumors were obtained after the final follow-up
MR examination (i.e., 14 days after the start of VEGF
receptor antibody treatments).
For histological comparisons with each of the time points
of the MRI examination, a second study with 10 additional
tumor-bearing animals was performed. At 1, 2, 4, and 7 days
after start of the VEGF receptor antibody treatment, one
treated and one control animal were examined with dynamic
contrast-enhanced magnetic resonance imaging (DCE MRI)
and sacrificed immediately after the examination.
Anesthesia and Application of Contrast Agent
For MR examination and catheterization, mice were
anesthesized by inhalation of a mixture of isofluorane
(1.5%), N2O (35%), and O2 (60%). A tail vein was cathe-
terized using a 30-gauge needle connected to a 10-cm-long
PE 10 polyethylene catheter (Portex, Medic-Eschmann,
Germany) filled with 10 ml of 0.9% NaCl. Successful puncture
of the mouse tail vein was controlled by blood reflux into the
catheter and by injection of 30 ml of 0.9% NaCl. The needle
was fixed on the mouse tail with superglue. The distal end of
the catheter was connected with a 30-cm-long PE 50 poly-
ethylene catheter (Portex) and a 1-ml tuberculin syringe,
both containing the contrast agent. After each examination,
the needle was removed from the tail vein.
Gadolinium diethylenetriaminepentaacetic acid (Gd-
DTPA) (Magnevist Schering, Berlin, Germany) was diluted
1:5 in 0.9% NaCl. One hundred microliters of this solution
(0.4 mmol/kg Gd-DTPA) was injected manually as a bolus
within 5 seconds into the tail vein of nude mice.
MRI
MRI was performed on a clinical 1.5-T whole-body MRI
system (Siemens Magnetom Vision, Erlangen, Germany)
using a custom-made radiofrequency (rf) coil (‘‘animal reso-
nator’’) for rf excitation and signal reception [32].
All animals were examined with T1- and T2-weighted
spin-echo pulse sequences and with dynamic contrast-en-
hanced T1-weighted MRI using the following imaging par-
ameters: for T1-weighted spin-echo MRI: TR = 600
milliseconds; TE = 14 milliseconds, two acquisitions; TA =
3 minutes, 53 seconds; field of view = 60  80 mm; matrix =
192  256; slice thickness = 1 mm; voxel size = 1.0 
0.31  0.31 mm3; for T2-weighted fast (‘‘turbo’’) spin-echo
MRI: TR = 4000 milliseconds; TE = 96 milliseconds, one
acquisition; echo train length = 7; TA = 1 minute, 49 seconds;
field of view = 60  80 mm; matrix = 182  256; slice
thickness = 2 mm; voxel size = 2.0  0.33  0.31 mm3.
For dynamic contrast-enhanced T1-weighted MRI, we used
a spoiled gradient echo sequence fast low-angle shot
(FLASH): TR = 100 milliseconds; TE = 6.5 milliseconds; flip
angle a = 90j, one acquisition; TA = 8 seconds; field of view =
35  35 mm; matrix = 64  64; slice thickness = 2 mm;
voxel size = 2.0  0.5  0.5 mm3. During an overall
measurement time of 8 minutes, 60 measurements were
obtained, with six transversal slices covering the tumor
completely.
Analysis of Amplitude and kep Values
Following Gd-DTPA injection, signal intensity – time
curves were recorded. Analysis of the dynamic data was
based on the pharmacokinetic two-compartment model of
Brix et al. [36]. Compartment 1 is assumed to be the
intravascular extracellular space and compartment 2 is the
extravascular extracellular space (EES) [24,36]. After infu-
sion of the contrast agent, an exchange of contrast agent
between both compartments is assumed, described by the
rate constant kep. kep is closely related to the downslope of
the signal intensity–time curve. Another commonly used
functional parameter is the amplitude A—the relative change
in signal intensity after the contrast agent injection relative
to precontrast values.
Based on this model, the measured data were analyzed.
The signal time course was fitted by a Levenberg-Marquard
algorithm to the following model equation:
SKM
SO
ðtÞ ¼ 1þ A
s
 kepe
kelðtt lagÞ
kelðkep  kelÞ ðe
kelt
V  1Þ  e
kepðtt lagÞ
kep  kel ðe
kept
V  1Þ
 
with the amplitude:
A ¼ D  Vp
Vplasma
 kpe
kep
 f1ðTR;TE;T10; ; Þ
and
t V ¼
0 : t < t lag
t  t lag : t lag < t < sþ t lag
s : t > sþ t lag
8>>><
>>:
The fitting parameters were A, kep, the renal elimination
constant kel, and the time delay of signal enhancement tlag.
The amplitude A is proportional to the contrast agent dose D
and the fraction of blood volume to voxel volume vp. It is
antiproportional to the whole-body plasma volume Vplasma
because a higher total plasma volume of the animal results in
a higher dilution of the contrast media and thus in a lower
amplitude. Furthermore, A depends on sequence and tissue
parameters as well as the repetition time TR, the echo time
TE, the baseline T1time T1.0, and the contrast agent
relaxivities a and b.
The parameters were calculated pixelwise, color-coded,
and overlaid on the morphological MR images.
Additionally, to enable a quantitative comparison of tumor
amplitude and kep of treated and untreated tumors, regions of
interest (ROIs) were drawn, using the computer mouse, in
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the MR slice with the largest tumor extent for each animal
and every examination.
For each tumor, three ROIs were drawn (Figure 1): one
including the total tumor, the second placed in the tumor
center, and the third at the tumor periphery, as done in
previous studies [37,38]. The ROI in the tumor center cov-
ered the entire tumor cross-section, but spared the ‘‘tumor
periphery’’ (tumor base and tumor convexity), which was
defined as a rim approximately 2 mm thick aligned around
the entire tumor circumference. The ROI, which intended to
represent the tumor periphery, was drawn at the base of the
tumor, close to the interface with the apparently nontumo-
rous tissue beneath, but not along the tumor convexity
covered by skin. ROIs were placed in a consensus read by
three observers (F.K., N.F., and M.L.).
Tumor Volume Measurement
Tumor volume was determined by taking two diameters
[length (a) and width (b)] on the transversal MR image
with the largest tumor extent. Assuming the tumor to be
an ellipsoid body, the tumor volume V was calculated
(V = ab2p/6).
Histological and Immunofluorescence Examination
Prior to the final MR examination, a line was drawn on
the skin of the mice along the largest transversal extent of
the tumor, using a pen. This line was then positioned in the
middle of the animal resonator under visual control. After
excising the tumor, the histologic sections were cut in
parallel to this line. For histological diagnosis and assess-
ment of vital tissue and its vascularization, tumors were
dissected, covered with ‘‘tissue tek’’ (Sacura, Zoeterwoude,
The Netherlands), and frozen in liquid nitrogen vapor. Five-
micrometer-thick sections were cut with a Reichert-Jung
(Leica-Microsystems, Nussloch, Germany) Frigocut 2700
microtome. Blood vessels and tumor cells were visualized
by double immunofluorescence staining using a mono-
clonal antibody against PECAM (anti–CD 31; PharMingen,
San Diego, CA) and a DNA stain with Hoechst (Frankfurt,
Germany). Tissue sections were viewed by fluorescence mi-
croscopy using an Olympus AX-70 microscope (Olympus
America Inc., Melville, NY). Images were captured with an
analySIS color view 12 digital camera (Soft Imaging System,
Muenster, Germany) and morphometric analyses were per-
formed at  100 magnification using the analysis SIS (Soft
Imaging System) software. Three different fields in the tumor
center and at the tumor periphery were examined at  100
magnification on each section, and the area fraction of the
vessel immunofluorescence staining was determined.
Statistics
All statistical evaluations were performed by a profes-
sional statistician with the statistical program package SAS
for Windows (version 8E; SAS Institute Inc., Cary, NC).
Amplitude, kep, and tumor volumes of each mouse were
normalized to the value, which was obtained at the first
measurement to minimize preexisting differences between
treated and untreated tumors prior to starting the anti–VEGF
receptor 2 antibody treatment. Differences in the normalized
tumor volume and dynamic parameters of treated and un-
treated tumors were compared using the two-sided nonpara-
metric Wilcoxon two-sample test. P < .05 was determined to
be significant. Please note that dynamic data shown in
figures and graphs are not normalized in order to improve
the transparency of the manuscript.
Results
Monitoring of Tumor Volume
Heterotransplanted SCCs were grown for 2 weeks and
had reached a mean volume of 90 mm3 when treatment with
Figure 1. Sketch illustrating ROI positioning in the tumors for the determination of amplitude and kep values. One ROI was drawn including the total tumor
(dashed line), the second placed in the tumor center (dotted line), and the third at the tumor periphery (continuous line) but sparing the convexity.
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the VEGF receptor 2 blocking antibody, DC 101, started. As
early as 4 days after starting the DC 101 treatment, the mean
volume (± SD) of treated tumors was lower (190 ± 101 mm3)
compared with untreated ones (437 ± 396 mm3) (Figure 2).
However, due to high interindividual variability, no significant
difference was observed compared with the untreated
tumors at this date. On day 7, tumor volumes of treated
(153 ± 843 mm3) animals (596 ± 384 mm3) became signif-
icantly smaller (P = .03) than those of untreated ones. After
14 days of antibody treatment, the differences were more
evident (P = .02), with the mean volume of treated tumors of
84 ± 93 mm3, as compared to 1207 ± 822 mm3 of controls. At
this point of time, one tumor in the treatment group was even
no longer detectable by MRI.
Noninvasive MR Monitoring of Tumor Volume and
Tumor Perfusion
MR parameter maps of amplitude and kep were estab-
lished to noninvasively visualize changes in both tumor
volume and vascularization (Figure 3). During follow-up,
the amplitude decreased in both treated and untreated
tumors, which was most pronounced in tumor centers.
However, the decrease of amplitude was observed much
earlier in treated tumors than in the untreated controls
(Figure 3). After 2 days of treatment, spots in central tumor
parts started to display very low amplitudes. Two days later,
although tumor volumes still remained unchanged, the whole
center of the treated tumor homogeneously showed very low
amplitudes (Figure 3). Then, at 7 and 14 days after starting
the antiangiogenic treatment, the volumes of the treated
tumors markedly decreased. In contrast, untreated tumors
continuously increased in volume. As a general impression,
areas without increase of signal intensity (no measurable
amplitude and kep values) developed to a much lower
degree, and later than in treated animals. After 4, 7, and
14 days, all untreated tumors showed a mixed pattern of
large areas with high and low amplitudes and kep.
Comparison of MR Monitoring and Histological Parameters
To validate MR parameter maps, they were compared
with corresponding histological sections stained for tumor
vessels by immunofluorescence. Amplitude/kep parameter
maps of tumors at days 1, 2, and 4 after the start of the VEGF
receptor ant ibody treatment are shown with the
corresponding immunofluorescence images (Figure 4). All
histologically apparent structures above 2 mm diameter,
such as necrotic and solid tumor areas, respectively, were
clearly identified with amplitude/kep parameter maps in all
tumors analyzed.
The considerable decrease in amplitude levels in the
center of treated tumors that was observed during the first
week was mirrored by necrotic areas in the tumor center and
a large decrease in vessel density in immunofluorescence
images (Figure 5). After 7 days of treatment, only a small rim
with solid tumor tissue and persistent vessels remained (not
shown). After 2 weeks of treatment, when the volume of the
treated tumors hadmarkedly decreased, the necrotic centers
were abolished and the remaining peripheral tumor parts,
which continued to display high amplitudes, showed large
vessels at the tumor base and in the overlying skin.
Quantitative Evaluation of Tumor Perfusion
Amplitudes and kep were measured in ROIs covering the
total tumor, tumor center, and tumor periphery separately
(Figures 6 and 7). The behavior of the amplitudes of treated
and untreated tumors differed significantly, with respect to
the total tumor ROIs and the ROIs of the tumor center.
Amplitudes of the tumor periphery revealed no significant
difference throughout the experiment (Figures 6 and 7).
For the total tumor and tumor center, the differences in
amplitude between treated and untreated tumors were most
significant 4 days after starting antibody treatment. Although
the tumor volume showed no significant changes, the ampli-
tudes in treated tumors decreased by 64% in the total tumor
ROIs and by 84% in ROIs of the tumor center, whereas
amplitudes in untreated tumors decreased by only 30% for
the total tumor and by 40% for the tumor center (P = .02)
(Figure 6). After 7 days of therapy, amplitudes of total tumor
and tumor center rose again in the four treated tumors, which
were examined successfully at the last examination date,
reaching a mean amplitude of 39% and 72%, respectively,
above control (Figure 7). This increase was paralleled by a
significant decrease in tumor volume in the treated tumors.
Simultaneously, untreated tumors increased in volume and
started to display necrotic areas.
In contrast, the exchange rate constant kep, which is a
compound parameter highly influenced by vessel permeabil-
ity, did not change significantly in treated and untreated
tumors during follow-up, remaining comparable between
both groups (Figure 7).
In agreement with the change of MR amplitudes, histo-
logically determined microvessel density in the tumor centers
of untreated tumors continuously decreased during follow-
up. Furthermore, microvessel density in the centers of trea-
ted tumors decreased earlier and to a higher degree than in
the untreated ones. In concordance with the change of
amplitudes in tumor centers from 7 to 14 days, microvessel
density tended to become higher in treated than in untreated
tumors, thereby validating noninvasive MRI as a suitable
Figure 2.Mean tumor volumes of treated and untreated tumors (mean ± SD).
Treated tumors slowed growth and showed significantly lower tumor
volumes, whereas untreated tumors continuously increased volume.
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method for monitoring tumor vascularization under antian-
giogenic therapy (Figure 8A). In contrast, microvessel den-
sity in the tumor periphery did not change markedly during
the examination period (Figure 8B).
Discussion
Angiogenic switch is a key event in tumor progression to a
malignant, invasive, and ultimately metastasizing tumor,
making angiogenesis one of the most promising targets for
the novel concepts of cancer therapy. The efficacy of anti-
angiogenic treatments for tumor regression and suppression
of metastases has been demonstrated in animal models and
is continuously being improved [3,10,12]. However, the
monitoring of the kinetics of therapeutic response has been
proven difficult. It was predominantly the use of histological
methods needing extensive experimental protocols with a
large number of animals that has been successful so far. The
development of functional noninvasive monitoring methods
that can be performed without the need for high-field MR
scanners is therefore an urgent necessity.
In the work presented here, T1-weighted DCE MRI utiliz-
ing a 1.5-T whole-body MR scanner and the parameteriza-
tion with the two-compartment model of Brix et al. were used
to monitor the kinetics of changes in tumor vascularization in
nude mice treated with an anti–VEGF receptor 2 antibody.
The two-compartment model describes extravasation and
rediffusion of contrast agent between an intravascular and
an extravascular extracellular compartment. Although the
simple design may not consider the vascular tumor pathol-
ogy in all regards (some amounts of contrast media may, for
example, be trapped in necrotic regions or be eliminated by
lymphatic vessels), it has proven reliable in various experi-
mental and clinical studies [16,23,25–27]. Using a simple
model is of critical importance when small animals are
examined in a clinical scanner with a considerably low
signal-to-noise ratio.
One key parameter used for monitoring is the amplitude,
which reflects the increase in signal intensity relative to
precontrast values. It is assumed that the intravascular
fraction of contrast agent hardly contributes to the change
in signal intensity. Only the contrast agent that exits the
vessels and enters the interstitial space will be present in
amounts sufficient to cause relevant signal enhancement.
The more blood is present inside the tissue volume, the more
contrast agent will be delivered to the interstitial space, and
the higher will be the amplitude [23,37]. Indeed, it was shown
previously that the amplitude correlates significantly with
microvessel density in HaCaT-ras heterotransplant tumors
[38]. The exchange rate constant kep is a compound param-
eter, which is closely related to the slope of the signal–
intensity time curve and is considered to largely reflect vessel
permeability but also the vessel surface area and perfusion.
Which of these factors most determines kep will depend on
which process is the limiting one for the substance exchange
between the two compartments under given conditions.
Unfortunately, the validation of kep as parameter of ves-
sel permeability [23] is still missing due to the lack of
standardization with direct measurements. Whenever the
intention is to measure blood flow or volume, it is the most
serious limitation of the two-compartment model that the
estimations are based on indirect measurements of the
contrast agent’s entry into the extravascular space and not,
as in fast dynamic MRmeasurements (e.g., T2*-DCE MRI or
Figure 3. Follow-up of color-coded amplitude parameter maps of a treated and an untreated tumor, which was examined prior (0) and 1, 2, and 4 days after start of
the antibody treatment. Two days after start of antibody treatment, spots occurred in the tumor center, which did not show any contrast enhancement (arrows).
After 4 days, no enhancement was found and thus no amplitudes could be calculated in central tumor areas anymore (arrows). In contrast, the untreated tumor
increased volume continuously. Also in untreated tumors, a decrease on central amplitude values was observed was but less pronounced and started at later time
points. During these 4 days of treatment, no significant differences were observed in tumor volume between the treated and the untreated tumors.
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arterial spin labeling techniques), on the inflow of blood itself
into the tissue. As a precondition for using the two-compart-
ment model, the contrast agent has to be homogeneously
distributed in the whole circulation, which is usually guaran-
teed by a sufficiently high blood flow. Whenever the blood
flow is very low (e.g., in malignant tumors with irregular
vascularization), perfusion will become the limiting process,
and the exchange rate constant kep will be more influenced
by perfusion than by permeability. To reach a homogeneous
distribution of the contrast agent, in most previous clinical
studies, contrast agent was injected as an infusion, not as
bolus as in our study. The reason for us to use a bolus
injection was that 100 ml of contrast agent can hardly be
given as an infusion without a suitable injection pump, which
was not available in our case. However, circulation time of
the total blood volume in mice is only 8 seconds and thus
about 10 times faster than in humans [39]. Therefore, it can
be assumed that in mice, the contrast agent is homoge-
neously distributed within a few seconds, and the precondi-
tion for using the Brix et al. model is fulfilled. In order to
enlarge the sensitivity of the method, the contrast agent dose
was optimized such that amplitude was comparable to those
of human studies. Therefore, in our study, four times the
dose of Gd-DTPA as used in human studies was applied.
Although we do not know the local concentration of the
contrast agent in our presented model, inside the tumor,
we did not observe a T2 effect after contrast agent injection.
By comparing tumor volumes of treated and untreated
tumors, we could clearly demonstrate that tumors treated
with the inhibitory VEGF receptor 2 antibody, DC101, grew
much slower than controls or were even reduced in volume.
Although a prolonged growth was observed during the first
week, the volume reduction of treated tumors became most
prominent during the second week of treatment. In line with
previous results on colorectal cancers in patients treated with
an inhibitor of the VEGF receptor [40], effects on tumor
Figure 4. Color-coded parameter maps of amplitude/kep and the corresponding immunofluorescence images (bottom row) of treated and untreated tumors are
shown after 1, 2, and 4 days of VEGF receptor antibody treatment. Vessels were stained with a CD31 antibody (red). Tumor cells were visualized with Hoechst
DNA stain (blue). The treatment with the VEGF receptor antibody caused a decrease on amplitudes and a loss of tumor vessels, which was accentuated in tumor
centers. Bar = 5 mm.
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vascularization of the SCC xenografts preceded volume
reduction of tumors and were reflected by a decrease in
amplitude levels and microvessel density already within two
treatments after the first. During the second week of treat-
ment, tumor amplitudes rose again in treated animals, reach-
ing higher levels than in controls at 14 days posttreatment.
During this interval, the treated tumors continued to de-
crease in volume. There are several aspects that explain
this seemingly paradoxical result. The DC101 treatment
affects mainly the small immature vessels inside the tumors
that represent the major contributors to tumor nutrition.
Mature vessels (i.e., vessels with pericytes) or vessel
threads might be less influenced because they are less
dependent on angiogenic stimulation. The decrease of
microvascularization will have a strong effect on the tumor
cells, which become necrotic and then are degraded, caus-
ing tumor shrinkage. Due to the persistence of larger mature
vessels and the fact that higher vascularized areas of the
tumor periphery draw nearer due to the loss of tumor cell
mass, the reduction of intravascular volume and thus the
amplitude might not have kept pace with tumor shrinkage. At
the same time, the delineation of treated tumors, which had
reached very small volumes, is more difficult and the ROIs
may have not exclusively contained tumor tissues but also
included large subcutaneous vessels giving a high ampli-
tude. These mature vessels are not sensitive to the VEGF
receptor blockade, leaving them unaltered during treatment.
Furthermore, although treated tumors showed good perfu-
sion in the entire tumor after 2 weeks, continuously decreas-
ing amplitude values were found in untreated tumors during
the whole examination period. This is most likely due to the
development of hypoperfused central necroses during
the later stages of tumor growth that were rather dominant
in the histological sections [37]. As a consequence, we see a
significant decrease in amplitude in the tumor center, where-
as it was considerably less pronounced in the tumor periph-
ery. The results are also in line with those of intermittent
ultrasound, where a decrease in tumor perfusion and blood
volume was observed during the first week, followed by an
increase within the second week after starting VEGF recep-
tor 2 antibody treatment [41].
No significant differences between treated and untreated
animals were observed for kep, although VEGF highly
increases vessel permeability and vessel diameter, and thus
the vessel surface area [15]. As a consequence of blocking
VEGF effects, a decrease of vessel permeability was
expected, which was described in previous studies using
DCE MRI for heterotransplanted tumor models of brain [42],
breast [43], and colorectal cancers of patients [39]. Consid-
ering the fact that kep is influenced by both vessel perme-
ability and vessel surface area, kep should decrease if both a
reduction of vessel surface area (vasoconstriction) and
permeability occur. There are two explanations for the ob-
served unchanged kep during follow-up in this study: the early
treatment effects may have unexpectedly increased vessel
permeability by affecting the integrity of the vessel wall and
the resulting increase of kep may then be balanced by a
reduction of the vessel surface area (or blood flow, in case
Figure 5. Double immunofluorescence images recorded in the centers of an untreated (A) and a 4-day– treated HaCaT-ras tumor (B). Vessels were stained with a
CD31 antibody (red). Tumor cells were visualized with Hoechst DNA stain (blue). Compared with the control, the treated tumor shows a marked decrease in vessel
density (larger vessels are labeled with arrows). Bar = 200 m.
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this model is limited by perfusion), resulting in an unchanged
kep. The second possibility is that the integrity of the vascular
wall is not affected by the DC101 treatment at all and thus kep
remains unchanged. Due to higher sensitivity for larger
defects and pores of the vessel wall, which are typical marks
of immature neoplastic vascularization, macromolecular
contrast agents such as Gd-DTPA albumin [32] or Gd-
labeled graft polymers may be more suitable to work out
specific effects on vessel permeability [44,45]. However,
most of these contrast agents show a slow but long accu-
mulation in tumors, which limits their usability for follow-up
studies with close time intervals.
Summarizing our results, we have shown the high thera-
peutic potential of the DC101 antibody as antiangiogenic
treatment of human SCCs in nude mice. Using T1w DCE
MRI and the two-compartment model, early therapeutic
response, which preceded volume reduction of tumors,
was observed as early as 2 days after the first antibody
treatment. Maximum difference in tumor vascularization
between treated tumors and controls was reached after
4 days. However, at later therapy stages in collapsing
Figure 6. Amplitudes in treated and untreated tumors measured in ROIs of
the total tumor (A), tumor center (B), and tumor periphery (C) during the initial
4 days of treatment. Data are given as mean ± SD.
Figure 7. Amplitudes (A) and kep (B) of treated and untreated tumors
measured in ROIs of total tumors during the 14-day follow-up. Data are given
as mean ± SD. Amplitudes of treated tumors rapidly decrease during the initial
4 days of treatment, but then rise again and are higher than in the controls after
14 days. Amplitudes of untreated tumors decrease continuously. In contrast,
kep shows stable values over the whole examination period and no significant
differences are observed between treated and untreated tumors.
Figure 8. Microvessel densities (area fraction) measured in the tumor center
(A) and tumor periphery (B). At each time point, one treated and one
untreated tumor were examined. For each tumor in the center and the
periphery, microvessel density was determined in three different fields. The
median value and the higher and lower values (error bars) are given.
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tumors, there is a risk of misinterpretation caused by the
tighter grouping of vessels in the tumors, which induces an
increase of dynamic parameters.
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